PL3072529T3 - Kompozycja zawierająca wemurafenib i HPMC-AS - Google Patents
Kompozycja zawierająca wemurafenib i HPMC-ASInfo
- Publication number
- PL3072529T3 PL3072529T3 PL15160958T PL15160958T PL3072529T3 PL 3072529 T3 PL3072529 T3 PL 3072529T3 PL 15160958 T PL15160958 T PL 15160958T PL 15160958 T PL15160958 T PL 15160958T PL 3072529 T3 PL3072529 T3 PL 3072529T3
- Authority
- PL
- Poland
- Prior art keywords
- vemurafenib
- hpmc
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15160958.3A EP3072529B1 (en) | 2015-03-26 | 2015-03-26 | Composition comprising vemurafenib and hpmc-as |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3072529T3 true PL3072529T3 (pl) | 2018-04-30 |
Family
ID=52875469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15160958T PL3072529T3 (pl) | 2015-03-26 | 2015-03-26 | Kompozycja zawierająca wemurafenib i HPMC-AS |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3072529B1 (pl) |
| ES (1) | ES2642162T3 (pl) |
| PL (1) | PL3072529T3 (pl) |
| WO (1) | WO2016151065A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
| US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
-
2015
- 2015-03-26 EP EP15160958.3A patent/EP3072529B1/en not_active Not-in-force
- 2015-03-26 PL PL15160958T patent/PL3072529T3/pl unknown
- 2015-03-26 ES ES15160958.3T patent/ES2642162T3/es active Active
-
2016
- 2016-03-24 WO PCT/EP2016/056485 patent/WO2016151065A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP3072529A1 (en) | 2016-09-28 |
| WO2016151065A1 (en) | 2016-09-29 |
| EP3072529B1 (en) | 2017-07-05 |
| ES2642162T3 (es) | 2017-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258900A1 (zh) | 遞送方法和組合物 | |
| HK1243741A1 (zh) | 腫瘤壞死因子受體超家族(tnfrsf)結合劑 | |
| IL255577B (en) | Binding materials - tigit and their uses | |
| HK1251153A1 (zh) | 一種藥物組合物及其應用 | |
| HK1251183A1 (zh) | 生物綴合物及其用途 | |
| HK1252260A1 (zh) | 基於絲的保濕劑組合物及其方法 | |
| IL252967A0 (en) | Pharmaceutical preparations containing plasminogen and their uses | |
| HK1252026A1 (zh) | 藥物組合及其應用 | |
| HK1248729A1 (zh) | 細胞毒性hexim1肽和其用途 | |
| HK1245113A1 (zh) | 藥物組合物及其用途 | |
| EP3256098C0 (en) | DENTAL COMPOSITION AND USE | |
| GB2546439B (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
| HK1250915A1 (zh) | 組合物和其用途 | |
| IL254711B (en) | History of diazepine-indole and medicinal preparations containing them | |
| IL248863A0 (en) | Preparations containing il-31 and their use | |
| PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| PL3072529T3 (pl) | Kompozycja zawierająca wemurafenib i HPMC-AS |